NCT05274451
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: ROR1+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment with any adoptive T-cell therapy or anti-ROR1 therapy; Patients with symptomatic, unstable, untreated brain metastases or leptomeningeal disease – see trial for details
https://ClinicalTrials.gov/show/NCT05274451